GSK is executing a significant strategic transformation focused on R&D, specialty medicines, and vaccines, having nearly doubled organic R&D spending under CEO Emma Walmsley.
The company has a robust late-stage pipeline, expecting to launch 14 major products this decade, each with over £2 billion in sales potential, including five new drug and vaccine approvals anticipated this year.
GSK is heavily integrating AI and technology to enhance R&D productivity, having already accelerated its RSV vaccine trials by two years and aiming for a future AI-driven "lab in a loop" model.
Strategic restructuring, including the de-merger of the consumer health division (Haleon), has strengthened GSK's balance sheet, enabling increased investment in its core biopharma business and global manufacturing capabilities.
11 quotes
Concerns Raised
The high failure rate (90%) and significant cost of drug development.
Rising vaccine hesitancy and the spread of misinformation post-COVID.
Geopolitical risks to global supply chain security.
The growing threat of antimicrobial resistance (AMR), termed the 'slow pandemic'.
Opportunities Identified
A robust pipeline with 14 potential blockbusters launching this decade.
Leveraging AI and new technology platforms to accelerate R&D and improve success rates.
Leadership in high-growth vaccine markets, particularly with the world's first RSV vaccine.
Significant growth potential in the oncology business, which more than doubled in revenue last year.